New £750K global vaccine collaboration

iiDiagnostics (iiDX), a company formed by the Infection Innovation Consortium, and Canadian biotech Eyam Health have launched a collaboration to bring forward Eyam Health’s novel vaccine technology using advanced automated organoid models.

This £750,000 ($1,009 million) international initiative will combine Eyam’s advanced vaccine design and delivery platforms with world-leading automated organoid technology from iiCON’s lead partner, Liverpool School of Tropical Medicine (LSTM), to accelerate the R&D and testing of vaccines against infectious diseases.

Eyam is receiving advisory services and up to $455,000 CAD in funding from the National Research council of Canada Industrial Research Assistance Program (NRC IRAP) to support its participation in the project, which is included as part of the total funding amount, with the remainder of the funding provided by Innovate UK, part of UK Research and Innovation (UKRI) and iiDiagnostics.